Cargando…

Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy

BACKGROUND: Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients’ perception of treatment efficacy. The latter is strongly influenced by the confidence in the involved health care...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zettl, Uwe Klaus, Bauer-Steinhusen, Ulrike, Glaser, Thomas, Hechenbichler, Klaus, Hecker, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031257/ https://www.ncbi.nlm.nih.gov/pubmed/27653529 http://dx.doi.org/10.1186/s12883-016-0705-1

Ejemplares similares

Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study
por: Zettl, Uwe K, et al.
Publicado: (2013)

Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp)
por: Limmroth, Volker, et al.
Publicado: (2019)

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients
por: Hecker, Michael, et al.
Publicado: (2013)

Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy
por: Koczan, Dirk, et al.
Publicado: (2018)

Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b
por: Weller, Ivonne, et al.
Publicado: (2015)

Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors
por: Frahm, Niklas, et al.
Publicado: (2019)

Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study
por: Frahm, Niklas, et al.
Publicado: (2019)

Polypharmacy in patients with multiple sclerosis: a gender-specific analysis
por: Frahm, Niklas, et al.
Publicado: (2019)

Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Systematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis
por: Bühring, Jan, et al.
Publicado: (2021)

Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance
por: Hundeshagen, Alexander, et al.
Publicado: (2012)

Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms
por: Freiesleben, Sherry, et al.
Publicado: (2016)

Principles and Practical Considerations for the Analysis of Disease-Associated Alternative Splicing Events Using the Gateway Cloning-Based Minigene Vectors pDESTsplice and pSpliceExpress
por: Putscher, Elena, et al.
Publicado: (2021)

Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2021)

Abnormal Pre-mRNA Splicing in Exonic Fabry Disease-Causing GLA Mutations
por: Alfen, Franziska, et al.
Publicado: (2022)

Reduced Fragmentation of IGFBP-2 and IGFBP-3 as a Potential Mechanism for Decreased Ratio of IGF-II to IGFBPs in Cerebrospinal Fluid in Response to Repeated Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis
por: Hoeflich, Andreas, et al.
Publicado: (2021)

The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis
por: Frahm, Niklas, et al.
Publicado: (2020)

A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector
por: Farej, Ryan, et al.
Publicado: (2022)

Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy
por: Hecker, Michael, et al.
Publicado: (2023)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
por: Hendin, Barry, et al.
Publicado: (2018)

Interferon beta-1b for COVID-19
por: Shalhoub, Sarah
Publicado: (2020)

Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes
por: Hecker, Michael, et al.
Publicado: (2021)

Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing
por: Putscher, Elena, et al.
Publicado: (2022)

Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients
por: Seyfi, Shahram, et al.
Publicado: (2021)

Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from natalizumab to interferon beta
por: Zecca, Chiara, et al.
Publicado: (2014)

Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells
por: Derkow, Katja, et al.
Publicado: (2013)

Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy
por: Haker, Marie-Celine, et al.
Publicado: (2023)

Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis
por: Langhorst, Silvan Elias, et al.
Publicado: (2022)

Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart(®) Injector: Results of the Prospective Cohort Study REBIFLECT
por: Rieckmann, Peter, et al.
Publicado: (2022)

Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study
por: Jacques, F., et al.
Publicado: (2012)

Considering Personalized Interferon Beta Therapy for COVID-19
por: Dorgham, Karim, et al.
Publicado: (2021)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
por: Thamilarasan, Madhan, et al.
Publicado: (2013)

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China
por: Xu, Yan, et al.
Publicado: (2019)

Pregnancy outcomes in patients exposed to interferon beta-1b
por: Romero, Rebecca S, et al.
Publicado: (2015)

Specific protein-protein interactions limit the cutaneous iontophoretic transport of interferon beta-1B and a poly-ARG interferon beta-1B analogue
por: Dubey, S., et al.
Publicado: (2020)

Is a Ratio Scale Assumption for Physician Ratings Justified? Comment on “What Patients Value in Physicians: Analyzing Drivers of Patient Satisfaction Using Physician-Rating Website Data”
por: Konerding, Uwe
Publicado: (2020)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Immunomodulatory activity of interferon-beta
por: Kasper, Lloyd H, et al.
Publicado: (2014)

Interferons Alpha, Beta, and Omega
por: Meager, Anthony
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_qpc9eqnopk98rtopmoj1h0gkpr